...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Blood Medicine >Thrombin use in surgery: an evidence-based review of its clinical use
【24h】

Thrombin use in surgery: an evidence-based review of its clinical use

机译：凝血酶在外科手术中的使用：基于证据的临床使用回顾

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: When surgical ligation of bleeding fails, or is not possible, surgeons rely on a -number of hemostatic aids, including thrombin. This review discusses the history, pharmacology and clinical application of thrombin as a surgical hemostat. The initial thrombin was bovine in origin, but its use has been complicated by the formation of antibodies that cross-react with human coagulation factors. This has been associated with life-threatening bleeding and in some circumstances anaphylaxis and death. Human thrombin, isolated from pooled plasma of donors, was developed in an effort to minimize these risks, but its downsides are its limited availability and the potential for transmitting blood-borne pathogens. Recently a recombinant thrombin has been developed, and approved for use by the FDA. It has the advantage of being minimally antigenic and devoid of the risk of viral transmission. Thrombin is often used in conjunction with other hemostatic aids, including absorbable agents such as Gelfoam, and with fibrinogen in fibrin glues. The last part of this review will discuss these agents in detail, and review their clinical applications.
机译：摘要：当外科手术结扎出血失败或不可能进行手术时，外科医生会使用多种止血药，包括凝血酶。这篇综述讨论了凝血酶作为手术止血剂的历史，药理学和临床应用。最初的凝血酶起源于牛，但由于与人凝血因子交叉反应的抗体的形成，其使用变得复杂。这与威胁生命的出血以及某些情况下的过敏性反应和死亡有关。从捐献者血浆中分离出人类凝血酶是为了最大程度地减少这些风险而开发的，但其缺点是其可用性有限以及传播血源性病原体的潜力。最近，已经开发了重组凝血酶，并已被FDA批准使用。它具有最小的抗原性和没有病毒传播风险的优点。凝血酶通常与其他止血助剂（包括可吸收剂，例如Gelfoam）以及纤维蛋白胶中的纤维蛋白原结合使用。本文的最后一部分将详细讨论这些药物，并评估其临床应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号